Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Short-term Investments (2020 - 2024)

Xeris Biopharma Holdings filings provide 5 years of Short-term Investments readings, the most recent being $10.2 million for Q3 2024.

  • On a quarterly basis, Short-term Investments fell 48.72% to $10.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $10.2 million, a 48.72% decrease, with the full-year FY2023 number at $5.0 million, changed N/A from a year prior.
  • Short-term Investments hit $10.2 million in Q3 2024 for Xeris Biopharma Holdings, down from $20.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $96.2 million in Q4 2020 to a low of $5.0 million in Q4 2023.
  • Median Short-term Investments over the past 5 years was $24.7 million (2024), compared with a mean of $29.0 million.
  • Biggest five-year swings in Short-term Investments: crashed 72.16% in 2022 and later skyrocketed 112.78% in 2023.
  • Xeris Biopharma Holdings' Short-term Investments stood at $96.2 million in 2020, then plummeted by 63.45% to $35.2 million in 2021, then tumbled by 73.48% to $9.3 million in 2022, then plummeted by 46.35% to $5.0 million in 2023, then soared by 103.32% to $10.2 million in 2024.
  • The last three reported values for Short-term Investments were $10.2 million (Q3 2024), $20.0 million (Q2 2024), and $24.7 million (Q1 2024) per Business Quant data.